These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 10167341)

  • 1. Economic foundations of cost-effectiveness analysis.
    Garber AM; Phelps CE
    J Health Econ; 1997 Feb; 16(1):1-31. PubMed ID: 10167341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accounting for future costs in medical cost-effectiveness analysis.
    Meltzer D
    J Health Econ; 1997 Feb; 16(1):33-64. PubMed ID: 10167344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic analysis in dermatology.
    Ellis CN; Reiter KL; Wheeler JR; Fendrick AM
    J Am Acad Dermatol; 2002 Feb; 46(2):271-83. PubMed ID: 11807441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of patient preferences for comorbidities in cost-effectiveness analyses.
    Harris RA; Nease RF
    J Health Econ; 1997 Feb; 16(1):113-9. PubMed ID: 10167342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assigning values to intermediate health states for cost-utility analysis: theory and practice.
    Cohen BJ
    Med Decis Making; 1996; 16(4):376-85. PubMed ID: 8912299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis and policy choices: investing in health systems.
    Murray CJ; Kreuser J; Whang W
    Bull World Health Organ; 1994; 72(4):663-74. PubMed ID: 7923545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theory and methods of economic evaluation of health care.
    Johannesson M
    Dev Health Econ Public Policy; 1996; 4():1-245. PubMed ID: 10158916
    [No Abstract]   [Full Text] [Related]  

  • 8. Preference-based measures in economic evaluation in health care.
    Neumann PJ; Goldie SJ; Weinstein MC
    Annu Rev Public Health; 2000; 21():587-611. PubMed ID: 10884966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global cost-effectiveness of cataract surgery.
    Lansingh VC; Carter MJ; Martens M
    Ophthalmology; 2007 Sep; 114(9):1670-8. PubMed ID: 17383730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfalls.
    Bambha K; Kim WR
    Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):519-26. PubMed ID: 15167152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost, effectiveness, and cost-effectiveness.
    Diamond GA; Kaul S
    Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):49-54. PubMed ID: 20031812
    [No Abstract]   [Full Text] [Related]  

  • 12. Economic evaluation in health: a thumb nail sketch.
    Kernick DP
    BMJ; 1998 May; 316(7145):1663-5. PubMed ID: 9603756
    [No Abstract]   [Full Text] [Related]  

  • 13. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data.
    Willan AR; O'Brien BJ
    Health Econ; 1999 May; 8(3):203-11. PubMed ID: 10348415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assigning resources to health care use for health services research: options and consequences.
    Fishman PA; Hornbrook MC
    Med Care; 2009 Jul; 47(7 Suppl 1):S70-5. PubMed ID: 19536002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian estimation of cost-effectiveness ratios from clinical trials.
    Heitjan DF; Moskowitz AJ; Whang W
    Health Econ; 1999 May; 8(3):191-201. PubMed ID: 10348414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of basing health-care resource allocations on cost-utility analysis in the presence of externalities.
    Labelle RJ; Hurley JE
    J Health Econ; 1992 Oct; 11(3):259-77. PubMed ID: 10122539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The limits of cost-effectiveness analysis.
    Weintraub WS; Cohen DJ
    Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):55-8. PubMed ID: 20031813
    [No Abstract]   [Full Text] [Related]  

  • 18. The contingent valuation method in health care. An economic evaluation of Alzheimer's disease.
    Nocera S; Telser H; Bonato D
    Dev Health Econ Public Policy; 2003; 8():iii-xi, 1-116. PubMed ID: 15027158
    [No Abstract]   [Full Text] [Related]  

  • 19. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.
    Neumann PJ; Cohen JT; Weinstein MC
    N Engl J Med; 2014 Aug; 371(9):796-7. PubMed ID: 25162885
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus.
    Meltzer D; Egleston B; Stoffel D; Dasbach E
    Med Care; 2000 Jun; 38(6):679-85. PubMed ID: 10843315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.